Your Cart

CBD Explained: A Comprehensive Guide to Cannabidiol

Cannabidiol (CBD) is a naturally occurring cannabinoid found in the Cannabis sativa plant. It has attracted scientific interest because of its interactions with several biological systems and its investigation in medical research. However, CBD is often misunderstood, particularly regarding its differences from THC, its scientific evidence and its regulatory status.

This guide explains what cannabidiol is, where it comes from, how it differs from other cannabinoids, what researchers currently understand about it, and how CBD-related medicines are regulated in Australia. It also introduces important safety considerations and provides references to authoritative health and regulatory information.

Introduction to Cannabidiol

Interest in CBD has grown steadily in Australia as medicinal cannabis pathways have expanded and public awareness has increased. Many people first encounter the term through discussions of epilepsy treatments, pharmacy information, or general wellness claims. A clear understanding of the compound, its origins, its relationship to other plant chemicals, the state of the evidence, and the Australian regulatory framework helps separate established facts from speculation.

What Is CBD (Cannabidiol)?

Cannabidiol, commonly abbreviated as CBD, is one of more than 100 cannabinoids identified in the cannabis plant. It is a non-intoxicating phytocannabinoid. Unlike tetrahydrocannabinol (THC), CBD does not produce the psychoactive “high” associated with cannabis use.

What is CBD?

CBD was first isolated in the 1940s. Its chemical structure and many of its pharmacological properties have since been characterised in laboratory and clinical settings. In the body it interacts with multiple systems. It shows low affinity for the primary cannabinoid receptors (CB1 and CB2) and instead influences the endocannabinoid system indirectly while also acting on other targets, including certain serotonin receptors, transient receptor potential channels, and enzymes involved in endocannabinoid metabolism.

The only purified CBD medicine currently registered on the Australian Register of Therapeutic Goods (ARTG) is Epidyolex (cannabidiol oral solution), approved for specific severe epilepsy syndromes. Most other CBD-containing products available in Australia are unapproved medicines accessed under special regulatory pathways.

Where Does Cannabidiol Come From?

CBD is produced by the Cannabis sativa plant, primarily in the resin of its flowers and leaves. The plant synthesises cannabinoids in their acidic forms (such as cannabidiolic acid, or CBDA). Heat or time converts these acidic precursors into the neutral forms, including CBD, through a process called decarboxylation.

Two broad categories of cannabis plants are relevant. Industrial hemp cultivars are selected for low THC content and may contain useful levels of CBD. Higher-THC cannabis varieties can also produce CBD, and some medicinal extracts are derived from those plants. The CBD molecule itself is chemically identical regardless of the plant source. Differences between products arise from the overall cannabinoid profile, the presence of other plant compounds such as terpenes, residual extraction solvents, and the degree of purification.

Extraction commonly uses supercritical carbon dioxide or solvent-based methods, followed by refinement steps that can produce full-spectrum extracts (containing a range of cannabinoids and other plant constituents), broad-spectrum extracts (most cannabinoids except THC), or CBD isolate (highly purified CBD).

In Australia, industrial hemp is regulated under state and territory legislation. THC thresholds for industrial hemp typically sit at or below 1% in the leaves and flowering heads (with seed certification often requiring lower parental-crop levels). These thresholds are set by the applicable legal framework in each jurisdiction and are not a single universal national figure.

CBD vs THC: Understanding the Differences

THC and CBD are the two most abundant and widely studied cannabinoids, yet they produce markedly different effects. THC is the primary psychoactive constituent of cannabis. It acts as a partial agonist at CB1 receptors concentrated in the central nervous system and is responsible for the intoxicating effects of cannabis.

CBD has very low affinity for these receptors and does not produce intoxication. When both compounds are present in the same product, CBD can modulate some of the effects of THC. Both substances are metabolised by liver cytochrome P450 enzymes, which creates the potential for drug–drug interactions. The relative proportions of CBD and THC in a preparation strongly influence its pharmacological profile and its classification under Australian poisons scheduling.

A more detailed comparison of the two compounds appears in a dedicated article on CBD versus THC.

What Are Cannabinoids and How Are They Classified?

Cannabinoids are chemical compounds that interact with cannabinoid receptors or related signalling systems. They are conventionally grouped into three categories:

  • Phytocannabinoids – produced by the cannabis plant (THC, CBD, cannabigerol, cannabinol, cannabichromene and many others).
  • Endocannabinoids – produced by the human body (principally anandamide and 2-arachidonoylglycerol).
  • Synthetic cannabinoids – laboratory-made compounds designed to act on the same receptors.

The cannabis plant does not produce THC or CBD directly in their neutral forms. It first synthesises acidic precursors that are later converted by heat or aging. Different plant genetics and growing conditions determine the relative abundance of each cannabinoid. Beyond the major compounds, minor cannabinoids and terpenes may contribute to the overall biological activity of an extract, although the clinical importance of any “entourage effect” continues to be studied.

A fuller classification and discussion of individual cannabinoids is covered in a dedicated article on the subject.

What Does Scientific Research Say About CBD?

The strongest clinical evidence for CBD concerns certain severe, treatment-resistant childhood epilepsy syndromes. Randomised controlled trials have demonstrated that a highly purified CBD oral solution reduces seizure frequency in Dravet syndrome, Lennox-Gastaut syndrome, and seizures associated with tuberous sclerosis complex. These findings underpin the registration of Epidyolex in Australia and equivalent products in other jurisdictions.

Research into other potential applications—chronic pain, anxiety, sleep disturbance, inflammation and various neurological conditions—remains active. Preclinical studies and smaller clinical investigations have generated signals of interest, yet high-quality, large-scale evidence is still limited or inconsistent for most indications outside refractory epilepsy. Study designs, formulations, doses and patient populations vary widely, which complicates direct comparison. Systematic reviews generally conclude that while CBD is of scientific interest, more rigorous trials are required for the majority of claimed uses.

CBD and the Endocannabinoid System: An Introduction

The endocannabinoid system is a widespread signalling network that helps regulate mood, pain perception, appetite, sleep, immune responses and neuronal activity. It consists of endogenous ligands (endocannabinoids), cannabinoid receptors (mainly CB1 and CB2), and the enzymes that synthesise and degrade the endocannabinoids.

THC activates CB1 receptors directly. CBD interacts with the system more indirectly: it shows low orthosteric affinity, can act as a negative allosteric modulator at CB1, may influence CB2 signalling, and affects enzymes that control endocannabinoid levels. It also engages additional targets outside the classical endocannabinoid system. These multimodal actions help explain why CBD can produce physiological effects without the intoxicating profile of THC.

A more detailed exploration of the endocannabinoid system is available in a dedicated article.

Understanding CBD Regulation in Australia

In Australia, CBD is regulated as a medicine by the Therapeutic Goods Administration (TGA) under the Therapeutic Goods Act and the Poisons Standard (Standard for the Uniform Scheduling of Medicines and Poisons).

Preparations containing at least 98% cannabidiol (and no more than 2% other cannabinoids found in cannabis) are classified as Schedule 4 (Prescription Only) medicines. In 2021 the TGA created a Schedule 3 (Pharmacist Only) entry for certain low-dose oral, oromucosal or sublingual CBD products that meet strict criteria (maximum recommended daily dose of 150 mg for adults, ≥98% CBD, ≤1% other cannabinoids including THC, specific packaging and age restrictions). In practice, as of late 2026 no CBD products meeting the Schedule 3 criteria have been entered on the ARTG, so pharmacist-only supply of approved low-dose CBD has not become available.

The only cannabis-derived medicines currently registered on the ARTG are Epidyolex (cannabidiol) and Sativex (nabiximols, a balanced THC:CBD oromucosal spray). Most medicinal cannabis products prescribed in Australia are unapproved medicines. Access occurs primarily through the Special Access Scheme Category B (for individual patients) or the Authorised Prescriber pathway. Medical practitioners must provide clinical justification, and products must comply with quality standards including the Standard for Medicinal Cannabis (TGO 93).

State and territory legislation imposes additional requirements, particularly for Schedule 8 products containing higher levels of THC. Advertising of medicinal cannabis products to the public is tightly restricted. Recreational or adult-use cannabis remains illegal. Patients seeking CBD for a medical purpose should consult a registered medical practitioner who can assess suitability and navigate the relevant access pathways.

CBD Safety and Potential Medicine Interactions

CBD is generally well tolerated at the doses studied in clinical trials, yet it is not free of adverse effects or risks. Commonly reported side effects include fatigue or somnolence, diarrhoea, reduced appetite and changes in liver enzymes. Elevations in liver aminotransferases (ALT or AST) have been observed, particularly at higher doses and when CBD is combined with valproate; monitoring of liver function is therefore recommended in certain clinical settings.

Because CBD is metabolised primarily by cytochrome P450 enzymes (notably CYP3A4 and CYP2C19) and can inhibit some of these enzymes, it has the potential to interact with many other medicines. Clinically relevant interactions have been documented with certain antiseizure medications (especially clobazam, via increased exposure to its active metabolite) and may occur with other CYP substrates such as some anticoagulants, immunosuppressants and antidepressants. Combining CBD with other sedating agents can increase drowsiness.

Quality and accurate labelling of unapproved products can vary. Residual solvents, heavy metals, pesticides or incorrect cannabinoid content remain possible concerns. CBD does not appear to carry significant abuse or dependence potential according to available assessments, including those of the World Health Organization. Pregnant or breastfeeding people, children (outside specific approved indications), and individuals with significant liver disease should seek medical advice before use.

Frequently Asked Questions About CBD

What does CBD stand for?
CBD is the abbreviation for cannabidiol, a naturally occurring compound found in the cannabis plant.

Is cannabidiol the same as cannabis?
No. Cannabis is the plant. Cannabidiol is one specific chemical compound among more than 100 cannabinoids present in that plant.

What is the difference between CBD and THC?
THC is the main psychoactive cannabinoid and produces intoxication. CBD is non-intoxicating and interacts with the body’s systems through different mechanisms.

Is CBD psychoactive?
CBD is not intoxicating and does not produce a “high.” It can still exert measurable effects on the nervous system and other physiological processes.

What are phytocannabinoids?
Phytocannabinoids are cannabinoids produced by plants, principally the cannabis plant. They are distinct from the endocannabinoids made by the human body and from synthetic cannabinoids created in laboratories.

How is CBD regulated in Australia?
CBD is regulated as a medicine by the TGA. High-purity CBD is a Schedule 4 prescription medicine. A limited Schedule 3 pathway for low-dose products exists in the Poisons Standard but, as of late 2026, no such products are listed on the ARTG. Most access therefore occurs via prescription under the Special Access Scheme or Authorised Prescriber pathways.

What is the role of the TGA?
The Therapeutic Goods Administration is Australia’s national regulator of therapeutic goods. It evaluates medicines for quality, safety and efficacy, maintains the ARTG, administers the Special Access Scheme and Authorised Prescriber pathways, and enforces advertising and supply rules for medicinal cannabis products.

What is the difference between CBD oil and hemp seed oil?
Hemp seed oil is pressed from the seeds of the hemp plant and contains negligible amounts of cannabinoids. CBD oil is an extract concentrated from the aerial parts of the plant and is standardised for its cannabidiol content.

Conclusion

Cannabidiol is a non-intoxicating cannabinoid derived from the cannabis plant. It has an established role in the treatment of certain severe epilepsies and continues to be investigated for other conditions. Its interactions with the endocannabinoid system and additional biological pathways differ substantially from those of THC. In Australia it is regulated as a medicine, with access largely restricted to medical prescription pathways overseen by the TGA. Safety is generally favourable at appropriate doses, but drug interactions, liver enzyme effects and product quality require careful attention.

This article provides an introductory overview intended as a central educational resource. Readers seeking more detailed information on specific topics—cannabidiol chemistry, the broader family of cannabinoids, CBD versus THC comparisons, Australia’s full medicinal cannabis regulatory framework, the scientific research landscape, safety considerations, or the endocannabinoid system—can consult the dedicated articles planned within this educational series. Anyone considering CBD for a medical purpose should discuss it with a qualified healthcare professional who can evaluate individual circumstances, current evidence and lawful access options.

References and further reading

  • Therapeutic Goods Administration – Medicinal cannabis hub and Poisons Standard entries for cannabidiol.
  • Healthdirect Australia – Medicinal cannabis information.
  • New South Wales Health – Access and approvals for cannabis medicines (current as of 2026).
  • Devinsky et al. and related randomised trials of purified CBD in Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex (PubMed).
  • Clinical pharmacokinetic studies of CBD interactions with CYP enzymes and antiseizure medicines (e.g., Patsalos et al., Epilepsia).
  • World Health Organization assessments of CBD dependence and abuse potential.
  • Office of Drug Control – Medicinal cannabis licensing and product standards.

Publication note
Published: November 2026.
Last reviewed: November 2026.
This article is for educational purposes and does not constitute medical advice. Regulatory information is current at the time of review but may change; readers should consult the TGA and a registered medical practitioner for the most up-to-date guidance.

Leave a Reply

Your email address will not be published. Required fields are marked *

Worldwide shipping

We ship WorldWide

Easy 30 days returns

30 days money back guarantee

International Warranty

Offered in the country of usage

100% Secure Checkout

PayID / Bank Transfer / Visa